Palisade Bio, Inc. (PALI)
NCM – Real vaqt narxi. Valyuta: USD
1.92
-0.02 (-1.03%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NCM – Real vaqt narxi. Valyuta: USD
1.92
-0.02 (-1.03%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Palisade Bio, Inc., klinik rivojlanish bosqichidagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda terminal ileum va yo'g'on ichakka maqsadli yetkazib berish uchun mo'ljallangan og'iz orqali yuboriladigan fosfodiesteraza-4 inhibitörli prodruglarni ishlab chiqish bilan shug'ullanadi. Uning yetakchi klinik mahsulot nomzodi PALI-2108 bo'lib, u yallig'lanishli ichak kasalliklari, jumladan, yarali kolit va Fibrostenotik Kron kasalligi bilan og'rigan bemorlarni davolash uchun 1b bosqichli klinik sinovdan o'tmoqda. Kompaniya o'z birikmalarini ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha Giiant Pharma, Inc. bilan ilmiy hamkorlik va litsenziyalash shartnomasiga ega; Newsoara hamkorlikdagi rivojlanishini qo'llab-quvvatlashning yagona maqsadida Kaliforniya universiteti regisllari bilan litsenziyalash shartnomasi; va Newsoara Biopharma Co., Ltd. bilan hamkorlikdagi rivojlanish va tarqatish shartnomasi. Kompaniya 2001 yilda tashkil etilgan va Denver, Kolorado shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. James Izanec M.D. | VP & Head of Clinical Development |
| Dr. Joerg Heyer Ph.D. | Head of Translational Science & Medicine |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | President & Chief Medical Officer |
| Mr. Adarsh Patel M.B.A., M.S. | Head of Chemistry, Manufacturing & Controls |
| Mr. Daniel J. Larkins | Head of Global Regulatory Affairs |
| Mr. J. D. Finley | CEO, CFO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 8-K | pali-20260512.htm |
| 2026-04-29 | DEFA14A | formdefa14a.htm |
| 2026-04-17 | PRE 14A | formpre14a.htm |
| 2026-04-02 | 8-K | form8-k.htm |
| 2026-03-20 | 10-K | pali-20251231.htm |
| 2025-12-04 | 8-K | form8-k.htm |
| 2025-11-12 | S-8 | forms-8.htm |
| 2025-11-10 | 10-Q | pali-20250930.htm |
| 2025-11-03 | DEFA14A | formdefa14a.htm |
| 2025-10-28 | DEF 14A | formdef14a.htm |
| Mr. Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations |
| Mr. Ryker Willie | Senior VP of Finance & Corporate Controller |
| Ms. Sharon Skare Ph.D. | Vice President & Global Head of Clinical Operations |